Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in C3G or Primary IC-MPGN
NCT07746895Phase 4Recruiting
- Sponsor
- Sobi
- Start
- Aug 2026
- Primary completion
- Dec 2031
- Countries
- 14
01
Overview
A Phase 4 trial of pegcetacoplan in Complement 3 glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by Sobi. Started Aug 2026; status: recruiting.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NCT07746895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07746895.